Despite survival improvement with novel agents and use of autologous hematopoietic stem cell transplantation (HSCT), cure of patients with multiple myeloma (MM) remains anecdotal. Initial observations suggested that chronic GvHD was accompanied by an anti-myeloma effect after myeloablative HSCT, but unfortunately this procedure was hampered by high non-relapse mortality (NRM). To maximize the anti-myeloma effect and minimize NRM, we developed a non-myeloablative (NMA) regimen associated with a high incidence of chronic GvHD and tested its efficacy on patient survival and disease eradication. From 2001 to 2010, 92 patients aged ⩽ 65 years with a compatible sibling donor received autologous HSCT followed by an outpatient NMA allogeneic HSCT using a conditioning of fludarabine and cyclophosphamide. Patient median age was 52 years and 97% presented DurieSalmon stages II-III disease. After a median follow-up of 8.8 years, probability of 10-year progression free and overall survival were 41% and 62%, respectively. Although the cumulative incidence of extensive chronic GvHD was high (at 79%), the majority of longterm survivors were off immunosuppressive drugs by year 5 and NRM was low (at 10%). Together, our results suggest that potential MM cure can be achieved with NMA transplantation regimens that maximize graft-versus-myeloma effect and minimize NRM.
INTRODUCTION
Multiple myeloma (MM) patient outcome has been remarkably improved with immunomodulatory drugs and proteasome inhibitors, yet this disease remains incurable with a median survival of 4-7 years. [1] [2] [3] Induction chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) is currently the standard treatment for younger myeloma patients. However, relapse is the rule and median PFS after first line therapy is usually o 4 years. [4] [5] [6] Allogeneic HSCT represents a potential curative option for MM patients. Early studies using myeloablative regimens in patients with advanced disease have reported a PFS ranging from 34 to 70% at 4-6 years in those achieving CR after allogeneic transplant. [7] [8] [9] Factors associated with improved PFS included fewer treatments before transplant, grade I acute GvHD and presence of chronic GvHD. This protective effect of chronic GvHD, [10] [11] [12] [13] [14] response after donor lymphocyte infusion 15, 16 and the discovery of antibodies against highly expressed myeloma-associated Ags 17 following allogeneic transplant are additional clinical observations supporting the existence of a graft-versus-myeloma (GvMM) effect.
Recently, allogeneic HSCT has received less enthusiasm due to prohibitive (20-30%) non-relapse mortality (NRM) associated with myeloablative conditioning 11 and high relapse rates (50-70%), following non-myeloablative (NMA) transplant. 18 Several controlled trials comparing autologous transplant alone to a tandem approach have questioned the survival benefits of NMA allogeneic HSCT for newly diagnosed MM patients, leading to conflicting results. 19 However, these randomized studies used different HSCT conditioning regimens, GvHD prophylaxis and non-transplant strategies in the control arm with various follow-up durations, which make comparisons difficult. Nevertheless, some studies 11, 20 have reported long-term survival rates in the range of 20-30%.
We previously reported the short-term outcome of patients exposed to our fludarabine and cyclophosphamide-based outpatient NMA conditioning regimen. 21 We observed a high incidence of chronic GvHD (76.1%), and low incidences of classical acute GvHD (11.6%) and NRM (15.5%). We therefore hypothesized this particularly light NMA regimen would be optimal to promote a GvMM effect in newly diagnosed MM patients. In this article, we now report the long-term outcome of a large cohort of patients homogenously treated and document the long-term benefit of our proposed approach.
MATERIALS AND METHODS
This prospective phase II study was conducted at Hôpital MaisonneuveRosemont in Montreal, Quebec, Canada, a 597-bed tertiary care institution affiliated to the Université de Montréal and accredited by the Foundation for Accreditation of Cellular Therapy. In accordance with our HSCT program policy, patients were referred by community physicians for autologous transplant if they had newly diagnosed MM, and were ⩽ 65 years old and had either Durie-Salmon stage II or III disease or progressive stage I disease requiring treatment in the clinician's opinion. After an induction treatment with vincristine, adriamycin and dexamethasone (VAD; 2001-2007, n = 75) or a bortezomib-based regimen (2008-2010, n = 17), patients underwent autologous HSCT using melphalan 200 mg/m 2 . Allogeneic transplant was proposed 60-100 days after autologous transplant only to patients with a 6/6 HLA-matched sibling donor, after complete clinical recovery.
All patients were treated and followed at one site by the same medical team after both autologous and allogeneic HSCT. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki and this study was approved by our institutional review board. NMA allogeneic HSCT exclusion criteria included a creatinine clearance o60 mL/min, a cardiac left ventricular ejection fraction o40% and a carbon monoxide diffusion capacity o 50%. Patients with non-secretory disease were eligible. International staging system (ISS) 22 was evaluated retrospectively when available. Cytogenetic data were only available for a minority of patients as this test was not routinely performed at initial diagnosis by referring centers during the study period.
Allogeneic transplant was performed entirely on an ambulatory basis. The conditioning regimen included fludarabine 30 mg/m 2 and cyclophosphamide 300 mg/m 2 both IV for 5 days. The graft consisted of donor G-CSF-mobilized PBSC, with a target dose ⩾ 4 × 10 6 CD34 + cells/kg. GvHD prophylaxis included oral tacrolimus and mycophenolate mofetil. Tacrolimus, introduced at the beginning of the conditioning regimen in order to achieve therapeutic levels at the time of graft infusion, was initiated at 3 mg twice daily from day − 10 to day +50 (monitored thrice weekly until the target level of 8-12 nmol/L was reached, then weekly) and tapered completely by day +100 in absence of GvHD. Oral mycophenolate mofetil was given at 1000 mg twice daily from day +1 to day +50 without taper. Infectious prophylaxis, engraftment monitoring, acute/chronic GvHD grading and treatment have previously been described. 21, 23 No maintenance or consolidation therapy was used after either transplant.
Responses were categorized according to the International Myeloma Working Group criteria 24 retrospectively in patients enrolled before 2006 and prospectively afterwards. CR was not confirmed with a bone marrow examination after allogeneic HSCT since this exam was not mandatory at the time of apparent CR as per our protocol, except in patients with non-secretory disease. Consequently, CR according to the International Myeloma Working Group was not evaluable for a majority of patients. A bone marrow aspirate and biopsy was however performed in patients with suspicion of progressive disease, defined as either increasing level of pre-allogeneic transplant paraprotein, reappearance of initial paraprotein after a negative immunofixation or 24-h urine collection or at the time of occurrence of extra-medullary plasmacytomas. Patients were followed weekly in the outpatient clinic until day +100, then every 2 weeks for 3 months, then every 4-6 weeks until all immunosuppression was discontinued. All patients were assessed at least twice yearly thereafter. At each patient's visit, medical history, physical exam (with special attention to extra-medullary manifestations of relapse), blood counts, biochemistry analyses including assessment of renal and hepatic function were performed. Ig dosage and serum/urine protein immunofixation were done on day +100, +180 and +365, then at least twice yearly afterwards. Starting in 2009, serum-free light chain dosage was also obtained (Freelite, The Binding Site, CA, USA). All patients had yearly skeletal survey for 2 years after allogeneic HSCT, then whenever disease progression was suspected.
After a complete work-up including bone marrow aspirate and biopsy, patients with progressive disease following allogeneic HSCT were treated with three infusions of donor lymphocyte infusion ( The primary objectives of this study were to determine overall survival (OS), PFS and NRM after a NMA allogeneic transplant using a GvHD prophylaxis strategy associated with a high incidence of chronic GvHD. Secondary objectives included disease response after allogeneic transplant, incidences of classical acute GvHD according to Glucksberg criteria, 25 chronic GvHD using National Institutes of Health criteria, 26 causes of mortality and duration of immunosuppression. OS, PFS and NRM were defined as time from allogeneic HSCT to death, death or progression and death without progression, respectively. Probabilities of OS and PFS were estimated using the Kaplan-Meier method; cumulative incidences of relapse, NRM and GvHD were estimated taking competing risks into account. Regression analysis using Cox and Fine & Gray models were used to determine factors influencing outcomes. Activity of chronic GvHD was assessed by the proportion of alive patients on any systemic immunosuppressive medication. Statistical analyses were performed using Stata 12 (StataCorp. 2011, College Station, TX, USA) and R (version 3.1.0, 2014; The R Foundation for Statistical Computing, Vienna, Austria). Abbreviations: HSCT = hematopoietic stem cell transplant; ISS = International Staging System; neg = negative; pos = positive; PR = partial response; VAD = vincristine, adriamycin, dexamethasone; VGPR = very good partial response.
RESULTS
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NMA allogeneic transplant and multiple myeloma I Ahmad et al ⩾ 95% donor lymphoid cells, was achieved in all patients after NMA transplant at a median day of +45 (range: +35 to +71). Eighty-seven percent of patients achieved at least very good partial response after allogeneic HSCT. Median follow-up was 8.8 years. The cumulative incidence of classical grades II-IV acute GvHD at 6 months was 9% (confidence interval (CI): 4-17%; Figure 1a ), occurring at a median time of 110 days (range: 57-147 days). Only three patients suffered from grade III or IV acute GvHD. Overall, 79% (CI: 71-87%; Figure 1b ) of patients developed extensive chronic GvHD, with a median time of occurrence of 141 days (range: 66-392 days). Sixty patients presented with de novo chronic GvHD, 5 with quiescent and 11 with overlap features. Most commonly involved organs included mouth, skin, eyes and liver.
The cumulative incidence of NRM at 10 years was 10% (CI: 4-18%, Figure 2a ). Ten patients have died from other causes than refractory MM, including six from refractory GvHD, three from lung adenocarcinoma (one smoker) and one from invasive aspergillosis. The cumulative incidence of progression at 10 years was 49% (CI: 39-59, Figure 2b ). To date, 45 patients have relapsed. Six never received anti-MM treatment (five with rapidly progressive disease received palliative care, one with smoldering myeloma was observed), whereas 39 have been treated with at least one new drug (thalidomide, lenalidomide, bortezomib or pomalidomide). In these patients, the median number of lines of therapy was 2 (range: 1-6) and 5-year OS from first relapse was 49% (CI: 32-64, Figure 3 ). Five patients received donor lymphocyte infusion, only one (also treated with thalidomide) achieved CR and is currently alive without any immunosuppressive medication. The other four patients had no response and are alive on various anti-MM therapies. In total, 10 patients having relapsed (26%) were in ⩾ very good partial response at the time of last follow-up.
The 10-year PFS was 41% (CI: 30-52%; Figure 4a) , with a median of 4.3 years (2.6-not reached), whereas OS probability was 62% (CI: 51-72%; median not reached, Figure 4b ). In multivariate analysis, achieving at least PR before allogeneic HSCT was a significant protective factor for progression (hazard ratio (HR) 0.13, CI: 0.06-0.30, P o 0.01). Extensive chronic GvHD was also protective for progression (HR 0.27, CI: 0.09-0.88, P = 0.029). Similarly, achieving at least partial response before allogeneic HSCT was associated with better OS (HR 0.36, CI: 0.15-0.84, P = 0.018). However, the association between chronic GvHD and OS did not reach statistical significance.
Among the 56 patients currently alive, the probability of being on any systemic immunosuppressive treatment for GvHD was 38% (CI: 27-49%) at 5 years and 22% (CI: 7-39%) at 10 years ( Figure 5 ). Forty patients are in continued response without evidence of progression at the end of follow-up, including 11 still taking systemic immunosuppressive drugs, whereas 16 are alive but have relapsed after allogeneic transplant. Outcome details for each patient are presented in Figure 6 . Although the allogeneic NMA transplant was planned to be entirely performed as an outpatient, 35 patients (38%) were admitted at least once within the first 180 days, for a total of 47 admissions. The median number of days spent in hospital was 8, ranging from 1 to 72. The most common reason for admission was infection (n = 29), followed by acute or chronic GvHD (n = 12) and other causes (n = 6, including immune thrombocytopenia, severe anemia due to ABO incompatibility, drug-induced hepatitis, poor overall condition, hydration before graft infusion in the context of major ABO incompatibility and one unclear cause).
DISCUSSION
We present the long-term outcome of one of the largest cohorts of newly diagnosed MM patients treated with a tandem autologous/allogeneic HSCT approach using a matched sibling donor. Our allogeneic transplant conditioning regimen was selected to be as little myeloablative as possible, to ensure that the patients would benefit from immunotherapy without the common side effects associated with myeloablation, such as mucositis, neutropenia and infections leading to high NRM. Our very light allogeneic conditioning regimen combined with GvHD prophylaxis allowed NMA transplant to be performed on an outpatient setting in a majority (62%) of patients. Rapid immunosuppression tapering, completed by day +100 in the absence of GvHD, was chosen to promote a GvMM effect. In this study, we also aimed to take advantage of the possible protective effect of chronic GvHD on MM relapse. 11, 12 Our results challenge the commonly accepted belief that allogeneic HSCT is overly toxic and associated with prohibitive NRM. Despite complete discontinuation of preventive immunosuppression by day +100, we observed a very low incidence of grades II-IV acute GvHD. However, chronic GvHD developed in a majority of patients. Response to GvHD therapy, evaluated by the probability of taking any systemic immunosuppressive drugs, was similar to other reported studies, with 62 and 78% of survivors being able to discontinue all immunosuppressive drugs after 5 and 10 years, respectively. 27 Our tandem approach was associated with a remarkably low NRM rate of 10% at 10 years. Among the 10 patients who experienced NRM, the most common cause of death was refractory GvHD: only one died from infection.
Several phase II and III tandem transplant studies have been published over the past decade. 13, 20, [28] [29] [30] [31] [32] [33] [34] [35] GvHD incidences vary widely in these cohorts due to heterogeneity in conditioning regimens and prophylaxis used, notably whether anti-thymocyte globulin was administered or not. From these publications, the incidence of grades II-IV acute GvHD ranged from 25 to 58%, chronic GvHD from 7 to 70% and NRM from 0 to 41%. Our results compare favorably with the published literature and confirm that a tandem approach is a safe and efficacious in newly diagnosed MM patients. Systematic use of the comorbidity index might further improve the outcome after NMA transplant. 36, 37 Amongst the best results reported to date, OS and PFS at 10 years are 62 and 41%, with a long median follow-up of 8.8 years, 13, 20, [29] [30] [31] [32] [33] [34] [35] despite sub-optimal induction regimens by today's standards (VAD was administered to 82% of our patients). 38 The main factors explaining these favorable results are very low rates of acute GvHD and NRM. It is well recognized that grades II-IV acute GvHD is associated with deleterious outcome and lower PFS and OS. 12, 18, 20, 35, 39 Conversely, the favorable impact of chronic GvHD on relapse is another important result. We speculate that the higher incidence of chronic GvHD observed in our cohort directly correlates with a GvMM effect and possibly explains the impressive PFS observed in our study. Alternatively, because not all studies have observed a protective effect of chronic GvHD 27,40,41 on progression, unintentional selection of patients with good prognosis cytogenetics, an upfront tandem approach in newly diagnosed patients and the absence of T-cell depletion 14 in the conditioning regimen might have contributed to our excellent results.
Our cohort of 92 patients reflects clinical practice in a large transplant center, where a majority of patients are referred from the community and allotransplanted when deemed physically and mentally fit. Two of the most important currently used prognostic factors (ISS 22 and cytogenetic analysis 42 ) were not prospectively evaluated. Because of the long enrollment period initiated in 2001, ISS staging (which became available in 2005) and cytogenetics were only available for a minority of patients. Most of our patients came from smaller community hospitals, where β 2 -microglobulin level and FISH and/or karyotypes were not routinely obtained before induction treatment. To date, it remains uncertain whether a tandem approach can overcome poor risk factors, albeit there is some evidence in the literature that allogeneic transplant might have a positive impact in patients presenting with high-risk cytogenetics. 20, 35, 43, 44 In summary, over 40% of our 92 patients are long-term survivors without evidence of progression after a median follow-up of 8.8 years and may be cured. Our data add further support to the evidence of a sustainable GvMM effect potentially able to cure a subset of patients. [7] [8] [9] [10] 15, 16, [45] [46] [47] Our results are provocative and should be used to reactivate sound scientific discussion on the exact role of allogeneic transplant in the treatment of MM, 48, 49 as further research is needed to optimize the GvMM effect and identify patients who might best benefit from it. Patients with poor prognosis (ISS III, 22 high-risk cytogenetics 42 and plasma cell leukemia 50 ) or younger patients who have the most significant loss in years of life following a diagnosis of MM 51 should be targeted in priority for a tandem approach like ours. Proteasome inhibitors, immunomodulatory drugs and monoclonal Abs among others could bring additional clinical benefits if used after NMA allogeneic transplant. 52 Such combination approaches are giving additional hope to provide a cure to a disease currently considered incurable. Finally, efforts should also be directed toward a better prevention of debilitating chronic GvHD without impairment of the GvMM effect. Recent reports of the anti-GvHD effect of proteasome inhibitors are encouraging, and form another important avenue to explore. 53 
